Pharmacokinetic changes induced by vasomodulators in kidneys, livers, muscles, and implanted tumors in rats as measured by dynamic Gd‐DTPA‐enhanced MRI
- 1 December 1996
- journal article
- research article
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 36 (6), 868-877
- https://doi.org/10.1002/mrm.1910360609
Abstract
The effects of three physiologically different vasomodulators, angiotensin II (a vasoconstrictor), hydralazine (a vasodilator), and histamine (a permeability modulator), on the pharmaco‐kinetics of entry of small molecules (measured by Gd‐DTPA concentration) into normal and abnormal tissue were studied in rats implanted with R3230 AC tumors. Sequential dynamic Gd‐DTPA‐enhanced MRI studies, one before and one after vasomodulator administration, were performed, and the signal intensities of various tissues analyzed. Angiotensin II (6 μg/kg) reduced blood flow in tumors, but increased it in muscles. Hydralazine (5 mg/kg) reduced blood flow in tumors, kidneys, and livers, and slowed Gd‐DTPA clearance from tumors, livers, and muscles. Histamine (25 μg/kg) increased renal blood flow, hastening Gd‐DTPA clearance causing reduced measurable blood flow in tumors and muscles. By simultaneously monitoring the effects in various tissues, the pharmacokinetic effect of each drug in the entire body could be obtained.This publication has 24 references indexed in Scilit:
- Comparative effects of hydralazine on perfusion of kht tumor, kidney and liver and on renal function in miceInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Monitoring blood flow to colorectal liver metastases using laser Doppler flowmetry: the effect of angiotensin IIBritish Journal of Cancer, 1992
- The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumoursBritish Journal of Cancer, 1992
- Fluctuations in Tumor Blood Flow under Normotension and the Effect of Angiotensin II‐induced HypertensionJapanese Journal of Cancer Research, 1991
- Regional chemotherapy for inoperable renal carcinoma: a method of targeting therapeutic microspheres to tumourBritish Journal of Cancer, 1991
- Effect of hydralazine on the blood flow in tumors and normal tissues in ratsInternational Journal of Radiation Oncology*Biology*Physics, 1991
- Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazineBritish Journal of Cancer, 1990
- Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugsInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazineBritish Journal of Cancer, 1988
- Pharmacoangiography with AngiotensinRadiology, 1974